首页> 美国卫生研究院文献>other >EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma
【2h】

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma

机译:EGFRvIII特异性嵌合抗原受体T细胞迁移并杀死侵袭性胶质母细胞瘤模型中浸润脑实质的肿瘤沉积物。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is uniformly lethal. T-cell-based immunotherapy offers a promising platform for treatment given its potential to specifically target tumor tissue while sparing the normal brain. However, the diffuse and infiltrative nature of these tumors in the brain parenchyma may pose an exceptional hurdle to successful immunotherapy in patients. Areas of invasive tumor are thought to reside behind an intact blood brain barrier, isolating them from effective immunosurveillance and thereby predisposing the development of "immunologically silent" tumor peninsulas. Therefore, it remains unclear if adoptively transferred T cells can migrate to and mediate regression in areas of invasive GBM. One barrier has been the lack of a preclinical mouse model that accurately recapitulates the growth patterns of human GBM in vivo. Here, we demonstrate that D-270 MG xenografts exhibit the classical features of GBM and produce the diffuse and invasive tumors seen in patients. Using this model, we designed experiments to assess whether T cells expressing third-generation chimeric antigen receptors (CARs) targeting the tumor-specific mutation of the epidermal growth factor receptor, EGFRvIII, would localize to and treat invasive intracerebral GBM. EGFRvIII-targeted CAR (EGFRvIII+ CAR) T cells demonstrated in vitro EGFRvIII antigen-specific recognition and reactivity to the D-270 MG cell line, which naturally expresses EGFRvIII. Moreover, when administered systemically, EGFRvIII+ CAR T cells localized to areas of invasive tumor, suppressed tumor growth, and enhanced survival of mice with established intracranial D-270 MG tumors. Together, these data demonstrate that systemically administered T cells are capable of migrating to the invasive edges of GBM to mediate antitumor efficacy and tumor regression.
机译:胶质母细胞瘤(GBM)是成人中最常见的原发性恶性脑肿瘤,具有致命的致死性。基于T细胞的免疫疗法为治疗提供了一个有希望的平台,因为它有潜力在不损害正常大脑的情况下专门针对肿瘤组织。然而,这些肿瘤在脑实质中的弥散性和浸润性可能给患者成功的免疫治疗带来一个特殊的障碍。浸润性肿瘤的区域被认为位于完整的血脑屏障的后面,将它们与有效的免疫监视隔离开来,从而使“免疫上沉默的”肿瘤半岛的发展变得容易。因此,尚不清楚过继转移的T细胞是否可以迁移到介导GBM的区域并介导其退化。一个障碍是缺乏能准确概括人类GBM体内生长模式的临床前小鼠模型。在这里,我们证明D-270 MG异种移植物表现出GBM的经典特征,并产生在患者中见到的弥漫性和浸润性肿瘤。使用该模型,我们设计了实验来评估表达针对表皮生长因子受体EGFRvIII的肿瘤特异性突变的第三代嵌合抗原受体(CAR)的T细胞是否会定位并治疗侵入性脑内GBM。靶向EGFRvIII的CAR(EGFRvIII + CAR)T细胞在体外具有EGFRvIII抗原特异性识别能力,并且对天然表达EGFRvIII的D-270 MG细胞系具有反应性。此外,当全身给药时,EGFRvIII + CAR T细胞定位于浸润性肿瘤区域,抑制了肿瘤的生长,并增强了已建立颅内D-270 MG肿瘤的小鼠的存活率。总之,这些数据证明全身施用的T细胞能够迁移至GBM的侵入性边缘以介导抗肿瘤功效和肿瘤消退。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号